Cochlear Radiation Dose and Early Hearing Changes After Chemoradiotherapy for Head and Neck Cancer: A Single-Center Retrospective Cohort Study
- 1Department of ENT, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
- 2Department of Otolaryngology, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
Abstract
Background/Objectives: Hearing impairment is a frequent but under-recognized sequela of (chemo)radiotherapy for head and neck cancer (HNC). We assessed the frequency of early post-treatment hearing changes and their association with cochlear radiation exposure and concurrent platinum-based chemotherapy. Methods: We conducted a single-center retrospective cohort study of 70 consecutive patients with HNC treated with radiotherapy between November 2024 and September 2025. Patients receiving concurrent chemoradiotherapy (CRT, n = 48) were compared with patients receiving radiotherapy alone (RT, n = 22). The primary outcome was clinically documented post-treatment hearing change. Cochlear maximum point doses (Dmax) were extracted from treatment plans. Analyses included Fisher exact and Mann–Whitney U tests, Spearman correlations, Firth penalized logistic regression, a Cochran–Armitage trend test, and restricted cubic splines. Results: Post-treatment hearing changes were documented in 38/70 patients (54.3%): 58.3% after CRT versus 45.5% after RT alone (odds ratio (OR) 1.68, 95% confidence interval (CI) 0.61–4.49, p = 0.439). Mean cochlear Dmax was higher in patients with hearing change (median 5.5 vs. 2.5 Gy, p = 0.045) and correlated with the outcome (ρ = 0.244, p = 0.043), with hearing-change rates of 34.8%, 65.2%, and 65.2% across cochlear-dose tertiles (trend p = 0.038). In Firth regression adjusted for age, pre-treatment hearing loss, and concurrent CRT, the association was attenuated and not statistically significant (adjusted OR 1.31 per 10 Gy, 95% CI 0.82–2.08, p = 0.253), and it was attenuated further after accounting for tumor site (OR 1.09 per 10 Gy, 95% CI 0.66–1.80, p = 0.735), with oropharyngeal primary the strongest correlate of hearing change (OR 4.02, 95% CI 1.28–12.6). Paired audiograms were available in only 10 patients, seven of whom showed audiometric deterioration; a conductive component could not be excluded in 14/38 events. No patient exceeded the QUANTEC mean cochlear-dose constraint of 45 Gy. Conclusions: Early, clinically apparent hearing changes affected more than half of this contemporary cohort. The univariable association with cochlear dose did not persist after adjustment, particularly for tumor site, and the available audiometric data do not allow hearing changes to be attributed specifically to cochlear injury. These findings underscore the need for systematic baseline and follow-up audiometry rather than demonstrating that further cochlear-dose reduction would improve hearing outcomes.
Related
- Dietary Zinc Glycine Supplementation Attenuates Aging-Driven Cochlear Hair Cell Oxidative Injury and Hearing Loss
- Optimizing Cochlear Implant Programming in Single‐Sided Deafness and Asymmetric Hearing Loss: A Randomized Comparison of ESRT and Behavioral Methods
- Residual Hearing Loss After Chronic Cochlear Implantation in Guinea Pigs is Primarily Conductive
- Sequential chemoradiotherapy vs. radiotherapy alone or concurrent chemoradiotherapy after radical resection of stage IA2–IIA1 cervical cancer: a retrospective cohort study
- Durvalumab completion and re-administration after grade 2 radiation pneumonitis following concurrent chemoradiotherapy for unresectable stage III NSCLC: a single-center real-world study
BibTeX
@article{morgovan2026cochlear,
title = {{Cochlear Radiation Dose and Early Hearing Changes After Chemoradiotherapy for Head and Neck Cancer: A Single-Center Retrospective Cohort Study}},
author = {Anda-Ioana Morgovan and Nicolae Constantin Balica and Cristina Mihaela Negru and Kristine Guran and Alexandru Orasan and Mihaela Andreea Banta and Crina Oana Pintea and Adrian Mihail Sitaru and Horatiu Eugen Stefanescu},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207985},
url = {https://www.mdpi.com/2077-0383/15/20/7985},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cochlear Radiation Dose and Early Hearing Changes After Chemoradiotherapy for Head and Neck Cancer: A Single-Center Retrospective Cohort Study
AU - Anda-Ioana Morgovan
AU - Nicolae Constantin Balica
AU - Cristina Mihaela Negru
AU - Kristine Guran
AU - Alexandru Orasan
AU - Mihaela Andreea Banta
AU - Crina Oana Pintea
AU - Adrian Mihail Sitaru
AU - Horatiu Eugen Stefanescu
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207985
UR - https://www.mdpi.com/2077-0383/15/20/7985
AB - Background/Objectives: Hearing impairment is a frequent but under-recognized sequela of (chemo)radiotherapy for head and neck cancer (HNC). We assessed the frequency of early post-treatment hearing changes and their association with cochlear radiation exposure and concurrent platinum-based chemotherapy. Methods: We conducted a single-center retrospective cohort study of 70 consecutive patients with HNC treated with radiotherapy between November 2024 and September 2025. Patients receiving concurrent chemoradiotherapy (CRT, n = 48) were compared with patients receiving radiotherapy alone (RT, n = 22). The primary outcome was clinically documented post-treatment hearing change. Cochlear maximum point doses (Dmax) were extracted from treatment plans. Analyses included Fisher exact and Mann–Whitney U tests, Spearman correlations, Firth penalized logistic regression, a Cochran–Armitage trend test, and restricted cubic splines. Results: Post-treatment hearing changes were documented in 38/70 patients (54.3%): 58.3% after CRT versus 45.5% after RT alone (odds ratio (OR) 1.68, 95% confidence interval (CI) 0.61–4.49, p = 0.439). Mean cochlear Dmax was higher in patients with hearing change (median 5.5 vs. 2.5 Gy, p = 0.045) and correlated with the outcome (ρ = 0.244, p = 0.043), with hearing-change rates of 34.8%, 65.2%, and 65.2% across cochlear-dose tertiles (trend p = 0.038). In Firth regression adjusted for age, pre-treatment hearing loss, and concurrent CRT, the association was attenuated and not statistically significant (adjusted OR 1.31 per 10 Gy, 95% CI 0.82–2.08, p = 0.253), and it was attenuated further after accounting for tumor site (OR 1.09 per 10 Gy, 95% CI 0.66–1.80, p = 0.735), with oropharyngeal primary the strongest correlate of hearing change (OR 4.02, 95% CI 1.28–12.6). Paired audiograms were available in only 10 patients, seven of whom showed audiometric deterioration; a conductive component could not be excluded in 14/38 events. No patient exceeded the QUANTEC mean cochlear-dose constraint of 45 Gy. Conclusions: Early, clinically apparent hearing changes affected more than half of this contemporary cohort. The univariable association with cochlear dose did not persist after adjustment, particularly for tumor site, and the available audiometric data do not allow hearing changes to be attributed specifically to cochlear injury. These findings underscore the need for systematic baseline and follow-up audiometry rather than demonstrating that further cochlear-dose reduction would improve hearing outcomes.
SN - 2077-0383
ER -